Pipeline & Portfolio
Therapies in motion.
Our pipeline reflects a deliberate strategy: focus on areas of high unmet need, partner with originators who have already done the hard work, and carry their therapies through to patients in markets that have been waiting too long.
A note on disclosure.
Amigen operates under confidentiality obligations with its originator partners. Specific product names, originator identities, and registration timelines are disclosed only where we have explicit permission to do so. The pipeline below reflects the therapeutic scope and stage of our current portfolio — not an exhaustive product-by-product listing.
Stage definitions
Evaluation
Therapy under commercial and regulatory assessment for in-licensing.
In-Licensed
Agreement executed; regulatory dossier preparation underway.
Registered
Marketing authorisation obtained in one or more target markets.
Commercialised
Therapy available to patients and actively distributed.
Current portfolio
Programs across five areas.
| Therapeutic area | Modality | Indication | Origin approval | Stage | Target markets |
|---|---|---|---|---|---|
| Anti-Infectives | Ceftazidime / Avibactam Injection | Gram-negative infections — carbapenem-resistant organisms | EMA / TGA approved | In-Licensed | GCCLevantNorth Africa |
| Anti-Infectives | Aztreonam / Avibactam Injection | Serious gram-negative infections — MBL-producing organisms | EMA approved | Evaluation | GCCLevant |
| Iron Deficiency | Ferric Carboxymaltose IV | Iron deficiency anaemia — IV replacement therapy | EMA / TGA / Health Canada approved | Registered | GCCNorth AfricaSub-Saharan Africa |
| Endocrinology & Metabolism | Semaglutide (GLP-1 agonist) | Type 2 diabetes / chronic weight management | EMA / TGA / Health Canada approved | In-Licensed | GCCNorth AfricaSoutheast Asia |
| Endocrinology & Metabolism | Liraglutide (GLP-1 agonist) | Type 2 diabetes / obesity | EMA / TGA / Health Canada approved | In-Licensed | GCCLevantSub-Saharan Africa |
| Oncology | L-Asparaginase | Acute lymphoblastic leukaemia (ALL) | EMA / Health Canada approved | Registered | GCCLevantNorth Africa |
| Anticoagulation | Rivaroxaban (oral Factor Xa inhibitor) | VTE prevention / treatment, stroke prevention in AF | EMA / TGA / Health Canada approved | Registered | GCCLevantCIS |
Gram-negative infections — carbapenem-resistant organisms
Ceftazidime / Avibactam Injection · EMA / TGA approved
Serious gram-negative infections — MBL-producing organisms
Aztreonam / Avibactam Injection · EMA approved
Iron deficiency anaemia — IV replacement therapy
Ferric Carboxymaltose IV · EMA / TGA / Health Canada approved
Type 2 diabetes / chronic weight management
Semaglutide (GLP-1 agonist) · EMA / TGA / Health Canada approved
Type 2 diabetes / obesity
Liraglutide (GLP-1 agonist) · EMA / TGA / Health Canada approved
Acute lymphoblastic leukaemia (ALL)
L-Asparaginase · EMA / Health Canada approved
VTE prevention / treatment, stroke prevention in AF
Rivaroxaban (oral Factor Xa inhibitor) · EMA / TGA / Health Canada approved
Our framework
What we look for.
Every program in our pipeline passed the same evaluation framework before we committed to it.
Proven efficacy
Phase III data or post-approval real-world evidence in the target indication.
Regulatory pathway clarity
A defined route to registration in our target markets, with reference to EMA, TGA, Health Canada, Medsafe, or ANVISA approval.
Unmet need
Meaningful gap between current standard of care and what this therapy offers patients in our markets.
Commercial viability
Addressable patient population and payer landscape that supports sustainable access.
Bring your therapy to our markets.
If you are an originator with an approved or late-stage therapy seeking a partner for emerging market registration and commercialisation, we want to hear from you.